Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RT-102 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| RT-102 (80 μg) | COMBINATION_PRODUCT | RaniPill capsule containing PTH with doses of 20 and 80 μg |
| Forteo | DRUG | A commercial formulation of PTH for SC control (20 µg) |
| RT-102 (20 μg) | COMBINATION_PRODUCT | RaniPill capsule containing PTH with dose of 20μg |
RT-102 is an investigational small molecule therapeutic developed by Rani Therapeutics Holdings, Inc. It is designed to be administered orally using the company's RaniPill capsule technology. RT-102 is in Phase 1 clinical development, and the specific disease or condition it is intended to treat has not been disclosed.
RT-102 is being developed by Rani Therapeutics Holdings, Inc., which trades under the ticker symbol RANI. The company is responsible for the clinical development of RT-102 and its associated RaniPill oral delivery platform.
RT-102 is in Phase 1 clinical development. One Phase 1 trial has been completed, and there are currently no active trials for RT-102. The completed study evaluated the pharmacokinetics of PTH administered orally via the RaniPill capsule in healthy volunteers.
RT-102 has been evaluated in one completed Phase 1 clinical trial, NCT05164614, titled "Study Evaluating PK of PTH Administered Orally Via RaniPill™ Capsule." The trial enrolled 50 healthy volunteers and was an uncontrolled study. No other clinical trials for RT-102 are currently listed as active.